Lv4
480 积分 2026-02-26 加入
500 - Patient-reported outcomes following 24 weeks of treatment with upadacitinib in adults with non-segmental vitiligo: results from a phase 2, randomized, double-blind, dose-ranging study
2个月前
已完结
Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial
2个月前
已完结
501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo
2个月前
已完结
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active nonsegmental vitiligo: results from a phase 2b, randomized, placebo-controlled, dose-ranging study
2个月前
已关闭
721 - Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
2个月前
已完结
Comparative efficacy of topical tofacitinib versus topical tacrolimus in the treatment of localized vitiligo: a randomized investigator-blinded intraindividual trial
2个月前
已完结
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
2个月前
已完结
17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics
2个月前
已完结
皖公网安备34019202002308
